Boston Scientific Corporation Could Lose $470 Million on Defib Recall, Might Sell Off Assets

MassDevice -- One analyst forecasts a $470 million loss over the next two years on Boston Scientific's defibrillator recall, while others say the company could look to sell off its pain management or neurovascular intervention units to cover the gap.